Ovalicin attenuates atopic dermatitis symptoms by inhibiting IL-31 signaling and intracellular calcium influx

Sung-Hyun Hwang; Yeseul Yang; Yeji Jeong; Yongbaek Kim

doi:10.7555/JBR.35.20210012

Volume 35 Issue 6

Nov. 2021

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2021 > 35(6): 448-458

Sung-Hyun Hwang, Yeseul Yang, Yeji Jeong, Yongbaek Kim. Ovalicin attenuates atopic dermatitis symptoms by inhibiting IL-31 signaling and intracellular calcium influx[J]. The Journal of Biomedical Research, 2021, 35(6): 448-458. doi: 10.7555/JBR.35.20210012

Citation:

Sung-Hyun Hwang, Yeseul Yang, Yeji Jeong, Yongbaek Kim. Ovalicin attenuates atopic dermatitis symptoms by inhibiting IL-31 signaling and intracellular calcium influx[J]. The Journal of Biomedical Research, 2021, 35(6): 448-458. doi: 10.7555/JBR.35.20210012

Citation:

PDF( 3999 KB)

Ovalicin attenuates atopic dermatitis symptoms by inhibiting IL-31 signaling and intracellular calcium influx

doi: 10.7555/JBR.35.20210012

Sung-Hyun Hwang^{1, 2},
Yeseul Yang^{1, 2},
Yeji Jeong^{1, 2},
Yongbaek Kim^{1, 3
,
,}

1.
Laboratory of Clinical Pathology, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea
2.
The Brain Korea 21 Future Veterinary Medicine Leading Education and Research Center, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea
3.
Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea

More Information

Corresponding author: Yongbaek Kim, Laboratory of Clinical Pathology, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea. Tel/Fax: +82-2-880-1273/+82-2-873-1213, E-mail: yongbaek@snu.ac.kr
Received: 2021-01-22
Revised: 2021-04-09
Accepted: 2021-04-14

Published: 2021-06-16

Issue Date: 2021-11-28

Abstract

Abstract

Atopic dermatitis (AD) is a common skin disorder difficult to be treated with medication. This study investigated the potential of ovalicin extracted from Cordyceps militaris for the treatment of AD using in vitro and in vivo models. We found that, in canine macrophage cell line DH82, lipopolysaccharide (LPS) upregulated the expression of genes associated with inflammation and pruritic responses through activating calcium and interleukin-31 (IL-31) signaling, and the upregulation could be suppressed by ovalicin, with an effect significantly stronger than dexamethasone. Ovalicin also reduced the expression of IL-31 downstream genes, including JAK2 (Janus kinase 2), TRPV1 (transient receptor potential vanilloid receptor-1), and HRH2 (histamine receptor H2). Ovalicin significantly alleviated the allergic symptoms in the AD mouse model. Histologically, the number of macrophages and mast cells infiltrated in the dermis was significantly reduced by ovalicin treatment. In the skin tissue of AD mice, reduction of IL-31 receptor was observed in the ovalicin treated group compared to the group without ovalicin treatment. To our knowledge, this is the first study to elucidate the anti-atopic mechanism of ovalicin, which could be an alternative to steroidal drugs commonly used for AD treatment.
- ovalicin,
- IL-31,
- pruritus,
- inflammation,
- calcium,
- atopic dermatitis

FullText(HTML)

References(32)

References

[1]	Hong J, Buddenkotte J, Berger TG, et al. Management of itch in atopic dermatitis[J]. SeminCutan Med Surg, 2011, 30(2): 71–86. doi: 10.1016/j.sder.2011.05.002
[2]	Wong LS, Wu T, Lee CH. Inflammatory and noninflammatory itch: implications in pathophysiology-directed treatments[J]. Int J Mol Sci, 2017, 18(7): 1485. doi: 10.3390/ijms18071485
[3]	Szepietowski JC, Reich A. Pruritus in psoriasis: an update[J]. Eur J Pain, 2016, 20(1): 41–46. doi: 10.1002/ejp.768
[4]	Hensel P, Santoro D, Favrot C, et al. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification[J]. BMC Vet Res, 2015, 11(1): 196. doi: 10.1186/s12917-015-0515-5
[5]	Simpson EL. Atopic dermatitis: a review of topical treatment options[J]. Curr Med Res Opin, 2010, 26(3): 633–640. doi: 10.1185/03007990903512156
[6]	Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: a long overdue revisit[J]. Indian Dermatol Online J, 2014, 5(4): 416–425. doi: 10.4103/2229-5178.142483
[7]	Bills GF, Gloer JB, An Z. Coprophilous fungi: antibiotic discovery and functions in an underexplored arena of microbial defensive mutualism[J]. Curr Opin Microbiol, 2013, 16(5): 549–565. doi: 10.1016/j.mib.2013.08.001
[8]	Yoon CS, Nam SH, Jeon JY, et al. Ovalicin ameliorates compound 48/80-induced atopic dermatitis-related symptoms[J]. Biol Pharm Bull, 2011, 34(12): 1881–1884. doi: 10.1248/bpb.34.1881
[9]	Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL-31-induced atopic dermatitis[J]. J Allergy Clin Immunol, 2018, 141(5): 1677–1689. doi: 10.1016/j.jaci.2017.12.1002
[10]	Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis[J]. Allergy, 2018, 73(1): 29–36. doi: 10.1111/all.13239
[11]	Takamori A, Nambu A, Sato K, et al. IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity[J]. Sci Rep, 2018, 8: 6639. doi: 10.1038/s41598-018-25094-4
[12]	Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1[J]. J Allergy Clin Immunol, 2014, 133(2): 448–460. doi: 10.1016/j.jaci.2013.10.048
[13]	Shim WS, Tak MH, Lee MH, et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase[J]. J Neurosci, 2007, 27(9): 2331–2337. doi: 10.1523/JNEUROSCI.4643-06.2007
[14]	Rao X, Huang X, Zhou Z, et al. An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis[J]. Biostat Bioinforma Biomath, 2013, 3(3): 71–85. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280562/
[15]	Kim H, Kim JR, Kang H, et al. 7, 8, 4′-Trihydroxyisoflavone attenuates DNCB-induced atopic dermatitis-like symptoms in NC/Nga mice[J]. PLoS One, 2014, 9(8): e104938. doi: 10.1371/journal.pone.0104938
[16]	Ku JM, Hong SH, Kim SR, et al. The prevention of 2, 4-dinitrochlorobenzene-induced inflammation in atopic dermatitis-like skin lesions in BALB/c mice by Jawoongo[J]. BMC Complement Altern Med, 2018, 18: 215. doi: 10.1186/s12906-018-2280-z
[17]	Ulmer AJ, Flad HD, Rietschel T, et al. Induction of proliferation and cytokine production in human T lymphocytes by lipopolysaccharide (LPS)[J]. Toxicology, 2000, 152(1-3): 37–45. doi: 10.1016/S0300-483X(00)00290-0
[18]	Ankers JM, Awais R, Jones NA, et al. Dynamic NF-κB and E2F interactions control the priority and timing of inflammatory signalling and cell proliferation[J]. Elife, 2016, 5: e10473. doi: 10.7554/eLife.10473
[19]	Yamaoka K, Okayama Y, Kaminuma O, et al. Proteomic approach to FcεRI aggregation-initiated signal transduction cascade in human mast cells[J]. Int Arch Allergy, 2009, 149(S1): 73–76. doi: 10.1159/000211376
[20]	Jou IM, Lin CF, Tsai KJ, et al. Macrophage-mediated inflammatory disorders[J]. Mediators Inflamm, 2013, 2013: 316482. doi: 10.1155/2013/316482
[21]	Hashimoto T, Kursewicz CD, Fayne RA, et al. Mechanisms of itch in stasis dermatitis: significant role of IL-31 from macrophages[J]. J Invest Dermatol, 2020, 140(4): 850–859. doi: 10.1016/j.jid.2019.09.012
[22]	Elmariah SB, Lerner EA. Topical therapies for pruritus[J]. Semin Cutan Med Surg, 2011, 30(2): 118–126. doi: 10.1016/j.sder.2011.04.008
[23]	Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch[M]//Cowan A, Yosipovitch G. Pharmacology of Itch. Berlin Heidelberg: Springer, 2015: 337–356.
[24]	Perron G, Dolbec P, Germain J, et al. Perineal pruritus after iv dexamethasone administration[J]. Can J Anaesth, 2003, 50(7): 749–750. doi: 10.1007/BF03018722
[25]	Kalthoff FS, Chung J, Stuetz A. Pimecrolimus inhibits up‐regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells[J]. Clin Exp Immunol, 2002, 130(1): 85–92. doi: 10.1046/j.1365-2249.2002.01962.x
[26]	Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group[J]. Arch Dermatol, 1995, 131(12): 1403–1408. doi: 10.1001/archderm.1995.01690240065010
[27]	Kwon CY, Lee B, Kim S, et al. Effectiveness and safety of herbal medicine for atopic dermatitis: an overview of systematic reviews[J]. Evid Based Complement Alternat Med, 2020, 2020: 4140692. doi: 10.1155/2020/4140692
[28]	Meister S, Plouffe DM, Kuhen KL, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery[J]. Science, 2011, 334(6061): 1372–1377. doi: 10.1126/science.1211936
[29]	Kittaka H, Tominaga M. The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin[J]. Allergol Int, 2017, 66(1): 22–30. doi: 10.1016/j.alit.2016.10.003
[30]	Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface[J]. QJM: Int J Med, 2003, 96(1): 7–26. doi: 10.1093/qjmed/hcg002
[31]	Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity[J]. Biochem Biophys Res Commun, 2009, 388(4): 621–625. doi: 10.1016/j.bbrc.2009.08.062
[32]	Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice[J]. Nat Immunol, 2004, 5(7): 752–760. doi: 10.1038/ni1084